The<unk>  of the drugs treating<unk> 's disease are problematic (approximately $170,000 US a year/patient) and remains a barrier to many patients in some countries. Enzyme replacement therapy (typically infused every two weeks) may be performed in the patient's home by the patients themselves. Enzyme replacement therapy is not a cure, and must be infused recurrently for maximum benefit.
Fabry's disease cost-effectiveness of therapy
Thin basement membrane disease cost-effectiveness of therapy
Diabetes dietary recommendations of american association of clinical endocrinologists
Tuberous sclerosis cost-effectiveness of therapy
Diabetes dietary recommendations of american diabetes association
Diabetes mellitus type 2 Cost-Effectiveness of Therapy
Gaucher's disease future or investigational therapies
Metabolic syndrome dietary therapy